From: Current status and future directions in the management of chronic hepatitis C
Groups | Overall SVR | SVR at end of follow-up | SVR by genotype | ||
---|---|---|---|---|---|
 |  |  | GT 1 | GT 2/3 | GT 4/5/6 |
Higher-dose peg-IFN + Rib | 65% P < 0.001 | 54% P = 0.01 | 42% | 82% | 50% |
Lower-dose peg-IFN + Rib | 56%, P = 0.41 | 47% P = 0.73 | 34% | 80% | 33% |
IFN + Rib | 54% | 47% | 33% | 79% | 38% |